BioNTech (NASDAQ:BNTX) Stock Price Target Lowered at HC Wainwright

Posted by George Bondi on Nov 9th, 2026

BioNTech (NASDAQ:BNTX – Get Free Report) had its price target cut by analysts at HC Wainwright from $130.00 to $110.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price objective indicates a potential upside of 25.70% from the stock’s current price.

BNTX has been the subject of several other reports. UBS Group decreased their price objective on BioNTech from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. Canaccord Genuity Group dropped their target price on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Morgan Stanley dropped their target price on shares of BioNTech from $114.00 to $106.00 and set an “overweight” rating on the stock in a report on Wednesday, November 4th. Bank of America reaffirmed a “buy” rating on shares of BioNTech in a research note on Wednesday. Finally, Wells Fargo & Company reduced their price target on shares of BioNTech from $140.00 to $125.00 and set an “overweight” rating for the company in a report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $122.27.

Get Our Latest Stock Report on BNTX

BioNTech Stock Performance

BNTX opened at $87.51 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.52 and a current ratio of 8.55. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00. The firm’s fifty day moving average is $94.66 and its two-hundred day moving average is $96.70. The firm has a market cap of $22.13 billion, a PE ratio of -12.78 and a beta of 1.28.

Insider Transactions at BioNTech

In other BioNTech news, CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the sale, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 807,209 shares of company stock worth $79,246,837 over the last 90 days. Corporate insiders own 19.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new stake in shares of BioNTech in the 2nd quarter valued at about $39,000. Farther Finance Advisors LLC lifted its stake in BioNTech by 31.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after purchasing an additional 118 shares during the last quarter. Parallel Advisors LLC grew its holdings in BioNTech by 50.3% during the third quarter. Parallel Advisors LLC now owns 843 shares of the company’s stock worth $83,000 after purchasing an additional 282 shares during the period. Quintet Private Bank Europe S.A. grew its holdings in BioNTech by 232.8% during the third quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock worth $188,000 after purchasing an additional 1,341 shares during the period. Finally, Sei Investments Co. bought a new position in BioNTech during the first quarter worth about $220,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

(Get Free Report)

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases.

The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio.

BioNTech works with partners to develop and distribute products internationally.